ArticleNature medicine2023
AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques.
Open access · hybridAbstract read
In one paragraph
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 43 citations in OpenAlex.
- Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial.Nature medicine · 2024Trial
- Article
- Opportunities and challenges in achieving a functional cure for HIV.Infectious diseases & immunity · 2026Review
- Limited Sex-Based Differences in Viral Outcomes of ART-Treated SIV/SHIV Infection.The Journal of infectious diseases · 2026Article
- AZD5582 robustly reactivates latently infected cells and clears the majority of those reactivated from the SIV reservoir.bioRxiv : the preprint server for biology · 2026Article
- Review
- Novel Insights into the Role of circRNAs in Cancer Immunotherapy Resistance and Clinical Implications.International journal of molecular sciences · 2026Review
- Delayed viral rebound post-ART interruption in infant macaques given SIV-specific neutralizing antibodies.Cell reports. Medicine · 2026Article
- Smac mimetic combined with eCD4-Ig reverses latency without reducing SHIV reservoirs in rhesus macaques.The Journal of clinical investigation · 2026Article
- A novel antiviral strategy by disrupting the equilibrium of virus-host calcium homeostasis.Current opinion in virology · 2026Review
- World free HIV: the novel therapeutic approaches for eliminating latent HIV infection.Virology journal · 2026Review
- Comparative In Vitro Evaluation of Anti-HIV Immunotoxin, Antibody-Drug Conjugate, and Radioimmunoconjugate Targeted by the Same Antibody.Antibodies (Basel, Switzerland) · 2026Article
- Searching for a HIV-1 Cure.Theranostics · 2026Review
- Lymphoid B cells upregulate HIV-1 ex vivo and are linked to its expression in vivo.PLoS pathogens · 2025Article
- Host-directed approaches in the pursuit of a cure for HIV.Antiviral research · 2025Review
- Immune-mediated strategies to solving the HIV reservoir problem.Nature reviews. Immunology · 2025Review
- A potent and broad CD4 binding site neutralizing antibody with strong ADCC activity from a Chinese HIV-1 elite neutralizer.Cell discovery · 2025Article
- Efficient mRNA delivery to resting T cells to reverse HIV latency.Nature communications · 2025Article
- Article
- Deep Thought on the HIV Cured Cases: Where Have We Been and What Lies Ahead?Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 8 institutions in 3 countries.
Amir DashtiDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-4679-7962
Sophia SukkestadDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-0877-0400
Anna M HornerDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Margaret NejaDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Zain SiddiqiDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Chevaughn WallerDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Jordan GoldyDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Dominique MonroeDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-5714-2518
Alice LinDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Nils SchoofDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Vidisha SinghDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Maud MavignerDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Claire DeleageAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-3507-0055
Marina TuyishimeDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Shane D FalcinelliUNC HIV Cure Center and Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-3554-226X
Hannah A D KingVaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
Ruian KeTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID http://orcid.org/0000-0001-5307-8934
Rosemarie D MasonVaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
Nancie M ArchinUNC HIV Cure Center and Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Richard M DunhamUNC HIV Cure Center and Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jeffrey T SafritImmunityBio, Inc., Culver City, CA, USA.
Sherrie JeanEmory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-8028-8160
Alan S PerelsonTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID http://orcid.org/0000-0002-2455-0002
David M MargolisUNC HIV Cure Center and Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-5714-0002
Guido FerrariDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Mario RoedererVaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
Guido SilvestriEmory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-6602-2470
Ann ChahroudiDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. ann.m.chahroudi@emory.edu.ORCID http://orcid.org/0000-0001-7479-9546
Emory University · USUniversity of North Carolina at Chapel Hill · USDuke Medical Center · USFrederick National Laboratory for Cancer Research · USLos Alamos National Laboratory · USNational Institutes of Health · USHenry M. Jackson Foundation · USImmunityBio (United States) · US
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI PENDLETON, RICHARD · 2019 to 2025
$3932.6MYerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MThe Center for Advancing Point of Care in Heart, Lung, Blood and Sleep DiseasesU54HL143541 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Nathaniel Scott Hafer · 2018 to 2026
$141.0MVirology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0MSocial and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5MB and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection - Administrative SupplementUM1AI124436 · NIAID · EMORY UNIVERSITY · PI AMARA, RAMA RAO, HUNTER, ERIC · 2016 to 2021
$42.3MB and T Cell Biology of Protection from and Eradication of SIV/SHIV InfectionUM1AI169662 · NIAID · EMORY UNIVERSITY · PI Rama Rao Amara, Eric Hunter · 2022 to 2026
$32.0MCollaboratory of AIDS Researchers for Eradication (CARE)UM1AI164567 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2021 to 2026
$31.6MCollaboratory of AIDS Researchers for Eradication (CARE)UM1AI126619 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARGOLIS, DAVID M. · 2016 to 2020
$23.2MStructure-Function Analytics CoreP01AI162242 · NIAID · DUKE UNIVERSITY · PI TOMARAS, GEORGIA DORIS · 2021 to 2025
$22.2MViral Testing Core-Maintenance of the SPF Breeding Colonies at Yerkes National Primate Research CenterU42OD011023 · OD · EMORY UNIVERSITY · PI Matthew Ryan Gardner · 2018 to 2026
$17.5MEnhanced latency reversal and reservoir clearance in macaquesR37AI157862 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi · 2021 to 2026
$5.4MCCR NIH HHS HHSN261200800001CNCI NIH HHS 75N91019D00024NCI NIH HHS HHSN261200800001ENHLBI NIH HHS U54 HL143541NIAID NIH HHS P01 AI046518NIAID NIH HHS P01 AI162242NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI028433NIAID NIH HHS R01 AI152703NIAID NIH HHS R37 AI157862NIAID NIH HHS UM1 AI124436NIAID NIH HHS UM1 AI126619NIAID NIH HHS UM1 AI164567NIAID NIH HHS UM1 AI169662NIH HHS P51 OD011132NIH HHS R01 OD011095NIH HHS U42 OD011023
Abstract
The main barrier to HIV cure is a persistent reservoir of latently infected CD4
Indexed as
HIV-1HIV InfectionsSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAlkynesAnimalsAntibodiesAnti-Retroviral AgentsCD4-Positive T-LymphocytesLymph NodesMacaca mulattaOligopeptidesViral LoadVirus LatencyVirus ReplicationAlkynesAntibodiesAnti-Retroviral AgentsN,N'-(2,2'-(hexa-2,4-diyne-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(1-(2-cyclohexyl-2-(2-(methylamino)propanamido)acetyl)pyrrolidine-2-carboxamide)Oligopeptides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.